{"id":"776abc17-e42b-5774-a383-6810009c985d","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-migraine-lowdose-crossover","predicate":"did_not_reduce_migraine_in_child_crossover","statement":"The 42-child crossover trial found no significant migraine-frequency reduction with 50 mg/day riboflavin; tension-type phenotype headaches showed a separate positive signal.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"714f2ec4-40d2-540c-8be7-0c0433a3497a","mechanism_event_label":"The type of headache and study exposure matter; a signal for a different headache endpoint is not proof of migraine prevention.","subject":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"object":{"id":"b7c15223-a4df-5d22-806a-01d8bc86b2a9","slug":"migraine-attack-frequency","display_name":"Migraine attack frequency","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"714f2ec4-40d2-540c-8be7-0c0433a3497a","stable_key":"548ab9d6-3a9b-5bed-879c-17d03813b636:b2-migraine-lowdose-crossover-event","event_type":"observed_intervention","label":"The type of headache and study exposure matter; a signal for a different headache endpoint is not proof of migraine prevention.","description":"The 42-child crossover trial found no significant migraine-frequency reduction with 50 mg/day riboflavin; tension-type phenotype headaches showed a separate positive signal.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"86eb1eee-a8d1-539c-8c17-0911f69b6f1b","slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"b7c15223-a4df-5d22-806a-01d8bc86b2a9","slug":"migraine-attack-frequency","display_name":"Migraine attack frequency","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"experimental_model","value_text":"42 children ages 6-13 in randomized crossover trial; 14 also had tension-type headache.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"50 mg/day riboflavin and placebo for 16 weeks each with four-week washout; pharmacological exposure.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Different dose from 200 mg trials, overlapping headache phenotypes and small sample; contextual result rather than a direct dose-matched contradiction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Riboflavin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"riboflavin","display_name":"Riboflavin (vitamin B2)","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The type of headache and study exposure matter; a signal for a different headache endpoint is not proof of migraine prevention.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[b2-bruijn2010] Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial (2010). https://pubmed.ncbi.nlm.nih.gov/20974610/ DOI: 10.1177/0333102410365106","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Children with migraine and some interval tension-type headache","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5c4c0f1d-f12f-5592-ab54-a580ea322c28","evidence_kind":"source_excerpt","locator":"Lines 1753-1763","start_line":1753,"end_line":1763,"excerpt":"### b2-migraine-lowdose-crossover\nThe 42-child crossover trial found no significant migraine-frequency reduction with 50 mg/day riboflavin; tension-type phenotype headaches showed a separate positive signal.\nCondition category: normal\nnutrient_topic: Riboflavin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The type of headache and study exposure matter; a signal for a different headache endpoint is not proof of migraine prevention.\norganism: Homo sapiens\ntissue_or_cell_type: Children with migraine and some interval tension-type headache\nexperimental_model: 42 children ages 6-13 in randomized crossover trial; 14 also had tension-type headache.\nlimitations: Different dose from 200 mg trials, overlapping headache phenotypes and small sample; contextual result rather than a direct dose-matched contradiction.\nexposure: 50 mg/day riboflavin and placebo for 16 weeks each with four-week washout; pharmacological exposure.\n[b2-bruijn2010] Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial (2010). https://pubmed.ncbi.nlm.nih.gov/20974610/ DOI: 10.1177/0333102410365106","model_system":"42 children ages 6-13 in randomized crossover trial; 14 also had tension-type headache.","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [b2-bruijn2010] Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, double-blind, cross-over trial (2010). https://pubmed.ncbi.nlm.nih.gov/20974610/ DOI: 10.1177/0333102410365106","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"4f7c9578-82bf-5e2d-b5c4-72a79fb4f6af","stable_key":"import-548ab9d6-3a9b-5bed-879c-17d03813b636","title":"Riboflavin: mechanisms, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"680cb6bc8249877f2410f551807f10d390fdd719014137d7414ba3420e29228d","revision_id":"7a61e299-908d-5372-860b-99ed190f9d7a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}